This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Elevance Looks Cheap Now: But is it Time to Buy or Dodge?
by Kaibalya Pravo Dey
Strong capital efficiency and commercial growth make ELV appealing, but regulatory and cost headwinds keep investors cautious.
UnitedHealth vs. Elevance: Which Healthcare Stock Has More Upside?
by Kaibalya Pravo Dey
ELV outpaces UNH with stronger earnings, leaner costs and clearer guidance, making it the healthcare stock with more upside right now.
Elevance Health (ELV) Down 6.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Analyst Reports for Walmart, Palantir & Uber
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), Palantir Technologies Inc. (PLTR) and Uber Technologies, Inc. (UBER).
UnitedHealth Spirals Downward Amid New Criminal Probe: Time to Sell?
by Kaibalya Pravo Dey
UNH's troubles are piling up, from a fresh DOJ criminal probe and rising costs to leadership shakeups and pulled guidance.
ENSG Gains 3% on Q1 Earnings Beat, Higher Patient Days Aid
by Zacks Equity Research
Ensign Group's first-quarter results gain on improved skilled services revenues and higher rental revenues. Management projects 2025 adjusted EPS to be within $6.22-$6.38.
Tenet Beats Q1 Earnings on Strong Ambulatory Unit, Ups '25 EPS View
by Zacks Equity Research
THC's first-quarter results benefit on the back of higher net revenue per case and the expansion of service lines within the Ambulatory Care unit. It currently expects 2025 adjusted EPS within $11.99-$13.12.
Encompass Health Beats Q1 Earnings Estimates, Ups '25 EPS View
by Zacks Equity Research
EHC's Q1 results benefit on the back of discharge growth and expansion endeavors, partly offset by high operating costs. It currently expects 2025 adjusted EPS from continuing operations within $4.85-$5.10.
Centene Q1 Earnings Beat Estimates on Marketplace Business Strength
by Zacks Equity Research
CNC's Q1 results benefit from improved premiums as a result of a strong PDP business, partly offset by elevated operating costs. It currently expects 2025 premium and service revenues within $164-$166 billion.
Wall Street Shaken as UnitedHealth Tanks Since Q1 Miss: Buy the Dip?
by Kaibalya Pravo Dey
From a valuation perspective, UNH appears expensive compared to its peers despite the drop in price.
Elevance Health's Q1 Earnings Beat Estimates on Rising Premiums
by Zacks Equity Research
ELV continues to witness significant growth in Q1 revenues. However, its operating costs surge.
Elevance Health (ELV) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Elevance Health (ELV) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Elevance Health (ELV) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 6.78% and 5.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Healthcare ETFs Tug of War: Insurers Tumble, Pharma Surges
by Sanghamitra Saha
Healthcare ETFs split as insurers stumble and pharma surges -- highlighting the necessity of smart industry picks.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Will a Strong MA Business Aid Elevance Health's Q1 Earnings?
by Zacks Equity Research
ELV's Q1 results are expected to reap the benefits of higher premiums from growing Medicare Advantage membership and acquisitions pursued within the Carelon unit.
Ahead of Elevance Health (ELV) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Elevance Health (ELV), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Elevance Health (ELV) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Elevance Health (ELV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Elevance Health (ELV) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Elevance Health (ELV) stock based on the movements in the options market lately.
Elevance Health (ELV) Soars 5.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Elevance Health (ELV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Harrow (HROW) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of 127.27% and 1.24%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Is UnitedHealth Stock Still a Buy Despite Its Premium Price Tag?
by Kaibalya Pravo Dey
UNH is making significant investments in AI and digital tools to enhance consumer experiences and streamline healthcare processes.